Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to take part and have signed a consent form agreeing to participate in the study.
- You are a man or woman between 18 and 75 years old (inclusive).
- You have been diagnosed with a type of bladder cancer (called non-muscle invasive bladder urothelial carcinoma) that has been confirmed by a tissue biopsy and is classified as high-risk or very high-risk.
- After a procedure to remove bladder tumors (called TURBT), there is no remaining removable tumor tissue (though a small surface-level cancer called CIS may still be present).
- Your doctor has decided that removing the bladder surgically is not appropriate for you, or you have chosen not to have that surgery.
- A test on your tumor tissue has shown a certain protein called HER2 at a level of 1+, 2+, or 3+.
- You are generally able to carry out daily activities with little to no limitation, based on a standard health scale (confirm with trial site).
- Your heart, blood, liver, kidney, and blood-clotting functions are all at healthy enough levels to participate.
Who may not be able to join:
- Your bladder cancer has grown deeper into the bladder wall (stage T2 or higher) or has spread to lymph nodes or other parts of the body.
- You have a related type of cancer in other parts of the urinary tract, such as the urethra, ureter, or kidney.
- You have received any other cancer treatment within the 4 weeks before starting this study.
- You are planning to have major surgery during the study or within 4 weeks before your first dose.
- You have a known allergy to the study drug (called DV) or any of its ingredients (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8610-58075763
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose-limiting toxicity(DLT) (Phase I); Incidence of Adverse event (Phase I); Recommended Phase II Dose(RP2D); Maximum Tolerated Dosage(MTD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.